Zealand Pharma's Weight Loss Drug Performs Well in Early Trials

Zealand Pharma's petrelintide shot has the potential to reduce body weight by more than 15% in longer trials, analysts from Jefferies write in a note following data from a 16-week trial that showed an 8.6% average weight loss. Results from the trial show petrelintide supports potential weight loss to a degree which is at least on par with GLP-1 medications that decrease appetite, such as Ozempic, but with an improved tolerability profile. The initial trial data also shows petrelintide could lead to higher quality and more sustainable weight loss through lean mass preservation, the analysts added.